Document is current
Any future updates will be listed below
-
Authors
Viñas Torné, Ramon https://orcid.org/0000-0003-2411-4478
Wiatrak, Maciej
Piran, Zoe https://orcid.org/0000-0003-0241-8948
Fan, Shuyang
Jiang, Liangze
Teichmann, Sarah A. https://orcid.org/0000-0002-6294-6366
Nitzan, Mor https://orcid.org/0000-0003-0074-9196
Brbić, Maria https://orcid.org/0000-0002-1120-1778
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (TMSGI2_226252, IC00I0-231922)
Peter und Traudl Engelhorn Foundation
European Union
- License Information
-
More Information
Article History
Received: 22 November 2024
Accepted: 14 July 2025
First Online: 25 August 2025
Competing interests
: M.W. is a part-time employee of Genentech. Z.P. is a full-time employee of Genentech. S.A.T. is a scientific advisory board member of ForeSite Labs, OMass Therapeutics and QIAGEN; a co-founder and equity holder of TransitionBio and EnsoCell Therapeutics; a non-executive director of 10x Genomics; and a part-time employee of GlaxoSmithKline. The remaining authors declare no competing interests.
